This analysis of antiosteoporosis therapy shows that 75% of patients have inadequate drug coverage and that adherence is strongly associated with age and administration regimen.
Lamberto Manzoli, MD, MPH
Advertisement
Articles by Lamberto Manzoli, MD, MPH
Advertisement
Latest Updated Articles
- Assessment and Potential Determinants of Compliance and Persistence to Antiosteoporosis Therapy in Italy
Published: May 19th 2014 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Howard A. “Skip” Burris, III, MD: An Oncology Pioneer Reflects on Patients, Progress, and Purpose
2
Advances in MASLD and MASH Care Highlight Progress and Persistent Gaps
3
New Bill Makes CMS Enforcer in PBM, Pharmacy Relationship: A Q&A With Jesse Dresser, Esq
4
Faricimab Safe, Effective for Use in Treating nAMD in Treatment-Naive Eyes
5